CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY
The new Treat-to-Target (T2T) strategy in the treatment of early psoriatic arthritis (PsA) is aimed at achieving remission or low disease activity. As of now, the new biological agent ustekinumb (UST), anti-interleukin (IL) 12/23 monoclonal antibodies, was used to treat psoriasis and PsA. The paper...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The new Treat-to-Target (T2T) strategy in the treatment of early psoriatic arthritis (PsA) is aimed at achieving remission or low disease activity. As of now, the new biological agent ustekinumb (UST), anti-interleukin (IL) 12/23 monoclonal antibodies, was used to treat psoriasis and PsA. The paper presents clinical observations of the efficacy of UST in early PsA treated according T2T strategy. The described clinical cases demonstrate that use of UST 45 mg both alone and in combination with methotrexate for early PsA with moderate and high activity reduced manifestations of peripheral arthritis and psoriasis, promoting rapid achievement of remission or minimal disease activity. Overall, UST is well tolerated by the patients. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |